HEALTH PROFESSIONAL · SOURCE READING
Prognostic factors associated with patient characteristics
Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for Childhood AML / Prognosis and Prognostic Factors
Age: Several reports have identified older age as an adverse prognostic factor.[11,24,25,27-29] The age effect is not large with regard to OS, but in general, the adverse outcomes seen in adolescents (≥16 years) compared with younger children appear to be primarily caused by increases in toxic mortality.[30] In the COG AAML1031 (NCT01371981) trial, age older than 11 years was an independent predictor of more favorable EFS on multivariable analysis.[31]While outcome for infants with acute lymphoblastic leukemia (ALL) remains inferior to that of older children, outcome for infants (<12 months) with AML is similar to that of older children when they are treated with standard AML regimens.[27,32-34] Infants have been reported to have a 5-year survival rate of 60% to 70%, but with increased treatment-associated toxicity, particularly during induction.[27,32-35]
Race and ethnicity: In both the Children's Cancer Group (CCG) CCG-2891 and COG-2961 (NCT00002798) studies, White children had higher OS rates than Black and Hispanic children.[24,36,37] Black children also experienced lower survival rates than White children in St. Jude Children’s Research Hospital AML clinical trials.[38] Further analysis revealed this disparity was primarily seen in patients who did not harbor core-binding factor variants and received standard induction therapy. This poorer outcome was attributed to a significantly higher prevalence of single nucleotide variants in genes involved in worse cytarabine metabolism in Black children than in White children.[39]
Down syndrome: For children with Down syndrome who develop AML, survival is generally favorable when diagnosed at a young age.[40-42] The prognosis is particularly good (EFS rate exceeding 80%) for children younger than 4 years at diagnosis, the age group that accounts for the vast majority of patients with Down syndrome and AML. Children older than 4 years have similar outcomes to patients without Down syndrome.[42-46]
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
- PubMed 11535502 · Original source
- PubMed 15644547 · Original source
- PubMed 16537811 · Original source
- PubMed 16642489 · Original source
- PubMed 18000167 · Original source
- PubMed 18076087 · Original source
- PubMed 21902686 · Original source
- PubMed 21968880 · Original source
- PubMed 22648558 · Original source
- PubMed 24104395 · Original source
- PubMed 24104597 · Original source
- PubMed 24837468 · Original source
- PubMed 28389462 · Original source
- PubMed 28400376 · Original source
- PubMed 28674028 · Original source
- PubMed 32029509 · Original source
- PubMed 34619758 · Original source
- PubMed 38753328 · Original source
- PubMed 9427716 · Original source
Preserved source evidence · Not medical advice
Triangle